Edition:
United States

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

102.40USD
22 Nov 2017
Change (% chg)

$-2.50 (-2.38%)
Prev Close
$104.90
Open
$105.00
Day's High
$105.35
Day's Low
$100.00
Volume
274,666
Avg. Vol
258,968
52-wk High
$136.90
52-wk Low
$28.35

Latest Key Developments (Source: Significant Developments)

PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA
Wednesday, 22 Nov 2017 09:15am EST 

Nov 22 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA.PUMA BIOTECHNOLOGY INC - ‍PUMA WILL RECEIVE UPFRONT AND MILESTONE PAYMENTS OF UP TO $4.5 MILLION THROUGHOUT TERM OF THE AGREEMENT​.PUMA BIOTECHNOLOGY-SPECIALISED THERAPEUTICS RESPONSIBLE FOR SEEKING REGULATORY APPROVALS, FOR COMMERCIALIZING NERLYNX IN SOUTH EAST ASIAN COUNTRIES.PUMA BIOTECHNOLOGY INC - ‍EXPECT TO HAVE REGULATORY APPROVAL FOR NERLYNX IN AUSTRALIA BY Q2 OF 2019​.  Full Article

Puma Biotechnology reports Q3 adj. loss per share $1.36
Thursday, 9 Nov 2017 04:07pm EST 

Nov 9 (Reuters) - Puma Biotechnology Inc :Puma Biotechnology reports third quarter 2017 financial results.Q3 adjusted non-GAAP loss per share $1.36.Q3 earnings per share view $-2.58 -- Thomson Reuters I/B/E/S.Q3 loss per share $2.07.  Full Article

Puma Biotechnology secures $100 mln term loan from Silicon Valley Bank and Oxford Finance
Thursday, 2 Nov 2017 04:20pm EDT 

Nov 2 (Reuters) - Puma Biotechnology Inc :Puma Biotechnology secures $100 million term loan from Silicon Valley Bank and Oxford Finance.Puma Biotechnology - ‍proceeds from financing will be used to continue to support Nerlynx commercial activities, ongoing research with neratinib ​.  Full Article

Puma Biotechnology reports Q2 loss per share $2.10
Wednesday, 9 Aug 2017 04:20pm EDT 

Aug 10 (Reuters) - Puma Biotechnology Inc -:Puma Biotechnology reports second quarter 2017 financial results.Q2 adjusted non-gaap loss per share $1.38.Q2 earnings per share view $-2.04 -- Thomson Reuters I/B/E/S.Q2 loss per share $2.10.Puma Biotechnology Inc - ‍anticipate that primary analysis of data related to nala trial will be available during first half of 2018​.  Full Article

U.S. FDA approves Puma's Nerlynx for extended adjuvant treatment of HER2-positive early stage breast cancer
Monday, 17 Jul 2017 05:36pm EDT 

July 17 (Reuters) - Puma Biotechnology Inc :U.S. Food and Drug Administration approves Puma's Nerlynx (neratinib) for extended adjuvant treatment of HER2-positive early stage breast cancer.Puma Biotechnology Inc - expects Neratinib to become commercially available in September 2017 and to be marketed as Nerlynx.  Full Article

Puma Biotechnology completes targeted enrollment in Neratinib Phase III metastatic breast cancer trial
Thursday, 6 Jul 2017 04:15pm EDT 

July 6 (Reuters) - Puma Biotechnology Inc ::Puma biotechnology completes targeted enrollment in neratinib phase iii metastatic breast cancer trial.Puma biotechnology inc says company anticipates that primary analysis of pfs will be available during first half of 2018.  Full Article

Partner Fund Management reports 8.1 pct passive stake in Puma Biotechnology
Monday, 5 Jun 2017 04:30pm EDT 

June 5 (Reuters) - Puma Biotechnology Inc : :Partner Fund Management LP reports 8.1 percent passive stake in Puma Biotechnology Inc as of May 24 .  Full Article

Puma Biotechnology Q1 adjusted non-GAAP loss per share $1.16
Wednesday, 10 May 2017 04:20pm EDT 

May 10 (Reuters) - Puma Biotechnology Inc ::Puma Biotechnology reports first quarter 2017 financial results.Q1 adjusted non-GAAP loss per share $1.16.Q1 earnings per share view $-1.98 -- Thomson Reuters I/B/E/S.Q1 loss per share $1.97.  Full Article

Caligor Opco says will support Puma Biotechnology's expanded access program for PB272 (neratinib) in U.S.
Wednesday, 12 Apr 2017 10:30am EDT 

Caligor Opco LLC: To support Puma Biotechnology's expanded access program for PB272 (neratinib) in United States .Also is providing regulatory, logistical, supply chain support for Puma's Managed Access Program for neratinib outside United States.  Full Article

Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272
Tuesday, 4 Apr 2017 01:05pm EDT 

Puma Biotechnology Inc : Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272 in extended adjuvant treatment of HER2-positive early stage breast cancer at the 2017 AACR annual meeting . Results of Phase II CONTROL trial showed incidence of grade 3 diarrhea for 137 patients who received loperamide prophylaxis was 30.7% . For 137 patients who received loperamide prophylaxis in Phase II CONTROL trial, 20.4% discontinued neratinib due to diarrhea .Reductions seen in incidence of severe neratinib-related diarrhea in CONTROL trial.  Full Article

BRIEF-PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA

* PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA